ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-08 18:00 |
Abivax stock included in MSCI Indexes
|
English | 11.0 KB | ||
| 2023-06-08 16:21 |
Abivax releases the results of its June 5, 2023 ordinary and extraordinary gene…
|
English | 7.3 KB | ||
| 2023-06-08 16:20 |
Abivax appoints Ida Hatoum as Chief People Officer
|
English | 12.3 KB | ||
| 2023-06-06 18:15 |
ABIVAX: Ida Hatoum est nommée Directrice des Ressources Humaines d’Abivax
|
French | 209.3 KB | ||
| 2023-05-24 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 248.5 KB | ||
| 2023-05-15 19:00 |
Abivax annonce son assemblée générale ordinaire annuelle et extraordinaire du 5…
|
French | 184.4 KB | ||
| 2023-05-15 19:00 |
Abivax announces its ordinary and extraordinary general meeting of June 5, 2023…
|
English | 10.0 KB | ||
| 2023-05-04 18:00 |
Abivax met à disposition son Document d’Enregistrement Universel 2023
|
French | 187.2 KB | ||
| 2023-05-04 18:00 |
Abivax publishes Universal Registration Document 2023 Document dEnregistrement …
|
English | 11.1 KB | ||
| 2023-05-04 17:01 |
URD Abivax 2023
|
English | 21.9 MB | ||
| 2023-05-02 18:00 |
Abivax : Publication d’une opinion d’expert dans la revue JCC sur obefazimod en…
|
French | 273.2 KB | ||
| 2023-05-02 18:00 |
Abivax: Publication of an expert article in JCC on obefazimod as promising ther…
|
English | 17.9 KB | ||
| 2023-04-28 19:00 |
Abivax postpones the publication of its 2023 Universal Registration Document
|
English | 175.6 KB | ||
| 2023-04-28 19:00 |
Abivax repousse la publication de son Document d’Enregistrement Universel 2023
|
French | 164.2 KB | ||
| 2023-04-21 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 247.0 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
